实用医学杂志 ›› 2024, Vol. 40 ›› Issue (8): 1175-1180.doi: 10.3969/j.issn.1006-5725.2024.08.027
• 综述 • 上一篇
收稿日期:
2023-09-14
出版日期:
2024-04-25
发布日期:
2024-04-19
通讯作者:
曾智桓
E-mail:gzzh@163.com
基金资助:
Qing ZHANG,Tudi LI,Rong CHEN,Zhihuan. ZENG()
Received:
2023-09-14
Online:
2024-04-25
Published:
2024-04-19
Contact:
Zhihuan. ZENG
E-mail:gzzh@163.com
摘要:
支架内再狭窄是经皮冠状动脉介入治疗术后并发症发生的主要原因之一,也是介入领域的难题。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是近年来用于治疗糖尿病的新型口服降糖药,除了能降低血糖,还具有降低血压、改善血脂、减重等功效,具有心血管保护作用。近期研究发现,SGLT2i可以降低支架内再狭窄的发生,显著改善接受介入治疗的冠心病患者的预后。本文将对SGLT2i在预防经皮冠状动脉介入治疗术后再狭窄相关的临床研究及其作用机制做一综述,为改善冠心病患者的临床预后提供新思路。
中图分类号:
张晴,黎土娣,陈荣,曾智桓. SGLT2i预防经皮冠状动脉介入术后支架内再狭窄的研究进展[J]. 实用医学杂志, 2024, 40(8): 1175-1180.
Qing ZHANG,Tudi LI,Rong CHEN,Zhihuan. ZENG. Research progress on sodium⁃glucose cotransporter 2 inhibitors for in⁃stent restenosis after percutaneous coronary intervention[J]. The Journal of Practical Medicine, 2024, 40(8): 1175-1180.
1 | 《中国心血管健康与疾病报告2022》编写组. 《中国心血管健康与疾病报告2022》要点解读 [J]. 中国心血管杂志, 2023, 28(4): 297-312. |
2 |
杨尚铭, 李首才, 耿超强, 等. 经皮冠状动脉介入术后支架内再狭窄的研究进展 [J]. 中西医结合心脑血管病杂志, 2023, 21(20): 3754-3760. doi:10.12102/j.issn.1672-1349.2023.20.013
doi: 10.12102/j.issn.1672-1349.2023.20.013 |
3 |
ERDOGAN E, BAJAJ R, LANSKY A, et al. Intravascular Imaging for Guiding In-Stent Restenosis and Stent Thrombosis Therapy [J]. J Am Heart Assoc, 2022, 11(22): e026492. doi:10.1161/jaha.122.026492
doi: 10.1161/jaha.122.026492 |
4 |
CONNELLY K, CAI S. Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function [J]. JACC Cardiovasc Imaging, 2021, 14(2): 408-410. doi:10.1016/j.jcmg.2020.08.020
doi: 10.1016/j.jcmg.2020.08.020 |
5 |
PACKER M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism [J]. Nat Rev Cardiol, 2023, 20(7): 443-462. doi:10.1038/s41569-022-00824-4
doi: 10.1038/s41569-022-00824-4 |
6 | MCMURRAY J J V, SOLOMON S D, INZUCCHI S E, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J]. N Engl J Med, 2019, 381(21): 1995-2008. |
7 |
YOUSSEF M E, YAHYA G, POPOVICIU M S, et al. Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control [J]. Int J Mol Sci, 2023, 24(7): 6039. doi:10.3390/ijms24076039
doi: 10.3390/ijms24076039 |
8 | MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J, 2021, 42(36): 3599-3726. |
9 | MCDONAGH T A, METRA M, ADAMO M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J, 2023, 44(37): 3627-3639. |
10 |
ELSAYED N A, ALEPPO G, ARODA V R, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023 [J]. Diabetes Care, 2023, 46(): S158-S190. doi:10.2337/dc23-er04
doi: 10.2337/dc23-er04 |
11 |
MARFELLA R, SARDU C, D'ONOFRIO N, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes [J]. BMC Med, 2023, 21(1): 71. doi:10.1186/s12916-023-02781-2
doi: 10.1186/s12916-023-02781-2 |
12 | 江耀辉, 王喆, 郑汝杰, 等. 达格列净对2型糖尿病药物洗脱支架植入后临床结局的影响 [J]. 临床心血管病杂志, 2021, 37(11): 1014-1019. |
13 |
任园园, 洪晋, 黄玉起, 等. 达格列净对2型糖尿病合并急性冠脉综合征患者PCI术后心功能和支架内再狭窄情况的影响 [J]. 河南医学研究, 2021, 30(17): 3117-3122. doi:10.3969/j.issn.1004-437X.2021.17.012
doi: 10.3969/j.issn.1004-437X.2021.17.012 |
14 |
刘家荣, 郑小鹏. 卡格列净对冠心病合并糖尿病患者冠脉药物洗脱支架内再狭窄的影响 [J]. 心血管病防治知识, 2022, 12(20): 15-18. doi:10.3969/j.issn.1672-3015(x).2022.20.004
doi: 10.3969/j.issn.1672-3015(x).2022.20.004 |
15 | 张海良, 张学丹. 老年急性STEMI患者PCI术后支架内再狭窄的危险因素Logistic回归分析 [J]. 临床医学研究与实践, 2019, 4(6): 86-87. |
16 | 张飞飞, 谢悦陶, 刘立天, 等. 经皮冠状动脉药物洗脱支架术后再狭窄影响因素分析 [J]. 实用医学杂志, 2020, 36(14): 1946-1951. |
17 | SABERZADEH-ARDESTANI B, KARAMZADEH R, BASIRI M, et al. Type 1 Diabetes Mellitus: Cellular and Molecular Pathophysiology at A Glance [J]. Cell J, 2018, 20(3): 294-301. |
18 |
SPADACCIO C, PATTI G, DE MARCO F, et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study) [J]. Am J Cardiol, 2013, 112(1): 21-26. doi:10.1016/j.amjcard.2013.02.046
doi: 10.1016/j.amjcard.2013.02.046 |
19 |
LEXIS C P, RAHEL B M, MEEDER J G, et al. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus [J]. Cardiovasc Diabetol, 2009, 8: 41. doi:10.1186/1475-2840-8-41
doi: 10.1186/1475-2840-8-41 |
20 | YAO D, WANG S, WANG M, et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑kappaB signaling pathway [J]. Mol Med Rep, 2018, 18(4): 3625-3630. |
21 |
SUN H, CHEN J, HUA Y, et al. New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation [J]. Diabetol Metab Syndr, 2022, 14(1): 121. doi:10.1186/s13098-022-00886-x
doi: 10.1186/s13098-022-00886-x |
22 |
JOUBERT M, JAGU B, MONTAIGNE D, et al. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model [J]. Diabetes, 2017, 66(4): 1030-1040. doi:10.2337/db16-0733
doi: 10.2337/db16-0733 |
23 |
DI PINO A, DEFRONZO R A. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents [J]. Endocr Rev, 2019, 40(6): 1447-1467. doi:10.1210/er.2018-00141
doi: 10.1210/er.2018-00141 |
24 | 楼善杰, 黄诚意, 刘旭. 冠心病非糖尿病患者胰岛素抵抗与支架内再狭窄相关性 [J]. 中华实用诊断与治疗杂志, 2015, 29(10): 1016-1018. |
25 |
ZHAO L P, XU W T, WANG L, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up [J]. Coron Artery Dis, 2015, 26(1): 5-10. doi:10.1097/mca.0000000000000170
doi: 10.1097/mca.0000000000000170 |
26 |
SASSO F C, PAFUNDI P C, MARFELLA R, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study [J]. Cardiovasc Diabetol, 2019, 18(1): 24. doi:10.1186/s12933-019-0826-0
doi: 10.1186/s12933-019-0826-0 |
27 |
张越, 王丽宏. 钠-葡萄糖共转运蛋白2抑制剂在改善胰岛素抵抗和胰岛β细胞功能方面的研究进展 [J]. 临床内科杂志, 2023, 40(3): 213-215. doi:10.3969/j.issn.1001-9057.2023.03.022
doi: 10.3969/j.issn.1001-9057.2023.03.022 |
28 |
NISHITANI S, FUKUHARA A, SHIN J, et al. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes [J]. Sci Rep, 2018, 8(1): 8805. doi:10.1038/s41598-018-27181-y
doi: 10.1038/s41598-018-27181-y |
29 |
BONNET F, SCHEEN A J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease [J]. Diabetes Metab, 2018, 44(6): 457-464. doi:10.1016/j.diabet.2018.09.005
doi: 10.1016/j.diabet.2018.09.005 |
30 |
YARIBEYGI H, SIMENTAL-MENDIA L E, BARRETO G E, et al. Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression [J]. J Cell Physiol, 2019, 234(10): 16987-16997. doi:10.1002/jcp.28420
doi: 10.1002/jcp.28420 |
31 |
CASON C A, KUNTZ T M, CHEN E B, et al. Microbiota composition modulates inflammation and neointimal hyperplasia after arterial angioplasty [J]. J Vasc Surg, 2020, 71(4): 1378-1389.e3. doi:10.1016/j.jvs.2019.06.208
doi: 10.1016/j.jvs.2019.06.208 |
32 |
NICULESCU R, RUSSU E, ARBANASI E M, et al. Carotid Plaque Features and Inflammatory Biomarkers as Predictors of Restenosis and Mortality Following Carotid Endarterectomy [J]. Int J Environ Res Public Health, 2022, 19(21): 13934. doi:10.3390/ijerph192113934
doi: 10.3390/ijerph192113934 |
33 |
谈昀, 马兰香, 张树苗, 等. 急性心肌梗死PCI术后支架内再狭窄患者的CRP、Hcy、CysC、NT-proBNP、LDL-C变化及临床意义 [J]. 海南医学, 2022, 33(14): 1799-1802. doi:10.3969/j.issn.1003-6350.2022.14.009
doi: 10.3969/j.issn.1003-6350.2022.14.009 |
34 |
王大鹏, 冯玉婧, 裴建军, 等. 药物涂层球囊扩张成形术对颈动脉支架内再狭窄患者术后再狭窄及炎症因子水平的影响 [J]. 中国医刊, 2023, 58(4): 409-412. doi:10.3969/j.issn.1008-1070.2023.04.017
doi: 10.3969/j.issn.1008-1070.2023.04.017 |
35 |
GASPARI T, SPIZZO I, LIU H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis [J]. Diab Vasc Dis Res, 2018, 15(1): 64-73. doi:10.1177/1479164117733626
doi: 10.1177/1479164117733626 |
36 |
ZHENG D, LIU J, PIAO H, et al. ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis [J]. Front Immunol, 2022, 13: 1039241. doi:10.3389/fimmu.2022.1039241
doi: 10.3389/fimmu.2022.1039241 |
37 |
SOARES R N, RAMIREZ-PEREZ F I, CABRAL-AMADOR F J, et al. SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice [J]. Geroscience, 2022, 44(3): 1657-1675. doi:10.1007/s11357-022-00563-x
doi: 10.1007/s11357-022-00563-x |
38 | 王聪霞, 贾珊. 冠状动脉支架内再狭窄发生机制的研究进展 [J]. 西安交通大学学报(医学版), 2018, 39(3): 303-309. |
39 |
BEHNAMMANESH G, DURANTE G L, KHANNA Y P, et al. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1 [J]. Redox Biol, 2020, 32: 101527. doi:10.1016/j.redox.2020.101527
doi: 10.1016/j.redox.2020.101527 |
40 |
PEYTON K J, BEHNAMMANESH G, DURANTE G L, et al. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1 [J]. Int J Mol Sci, 2022, 23(15): 8777. doi:10.3390/ijms23158777
doi: 10.3390/ijms23158777 |
41 |
DUTZMANN J, BODE L M, KALIES K, et al. Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration [J]. Front Cardiovasc Med, 2022, 9: 956041. doi:10.3389/fcvm.2022.956041
doi: 10.3389/fcvm.2022.956041 |
42 |
KASAI A, SHINTANI N, ODA M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells [J]. Biochem Biophys Res Commun, 2004, 325(2): 395-400. doi:10.1016/j.bbrc.2004.10.042
doi: 10.1016/j.bbrc.2004.10.042 |
43 |
ZHANG P, WANG A P, YANG H P, et al. Apelin-13 attenuates high glucose-induced calcification of MOVAS cells by regulating MAPKs and PI3K/AKT pathways and ROS-mediated signals [J]. Biomed Pharmacother, 2020, 128: 110271. doi:10.1016/j.biopha.2020.110271
doi: 10.1016/j.biopha.2020.110271 |
44 |
廖耿. 支架内再狭窄的分子学机制研究进展 [J]. 当代医学, 2013, 19(1): 10-12. doi:10.3969/j.issn.1009-4393.2013.1.006
doi: 10.3969/j.issn.1009-4393.2013.1.006 |
45 |
DURANTE W, BEHNAMMANESH G, PEYTON K J. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling [J]. Int J Mol Sci, 2021, 22(16): 8786. doi:10.3390/ijms22168786
doi: 10.3390/ijms22168786 |
46 |
AROOR A R, DAS N A, CARPENTER A J, et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury [J]. Cardiovasc Diabetol, 2018, 17(1): 108. doi:10.1186/s12933-018-0750-8
doi: 10.1186/s12933-018-0750-8 |
47 |
SHIGIYAMA F, KUMASHIRO N, MIYAGI M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study [J]. Cardiovasc Diabetol, 2017, 16(1): 84. doi:10.1186/s12933-017-0564-0
doi: 10.1186/s12933-017-0564-0 |
48 |
SAWADA T, UZU K, HASHIMOTO N, et al. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease [J]. J Atheroscler Thromb, 2020, 27(7): 644-656. doi:10.5551/jat.50807
doi: 10.5551/jat.50807 |
49 |
IRACE C, CUTRUZZOLA A, PARISE M, et al. Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study [J]. Diab Vasc Dis Res, 2020, 17(1): 1479164119883540. doi:10.1177/1479164119883540
doi: 10.1177/1479164119883540 |
50 |
HASHIKATA T, IKUTOMI M, JIMBA T, et al. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes [J]. Heart Vessels, 2020, 35(10): 1378-1389. doi:10.1007/s00380-020-01621-0
doi: 10.1007/s00380-020-01621-0 |
51 |
LEE H F, CHAN Y H, CHUANG C, et al. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors [J]. Eur Heart J Cardiovasc Pharmacother, 2023, 9(4): 301-310. doi:10.1093/ehjcvp/pvad004
doi: 10.1093/ehjcvp/pvad004 |
52 |
王法斌, 孙梦涵, 赵强, 等. 早期应用达格列净在急性心肌梗死急诊经皮冠状动脉介入术后患者中的有效性及安全性 [J]. 实用医学杂志, 2023, 39(13): 1688-1692. doi:10.3969/j.issn.1006-5725.2023.13.016
doi: 10.3969/j.issn.1006-5725.2023.13.016 |
53 |
盛雪, 纪征, 王兆翔, 等. 达格列净联合诺欣妥对急性心肌梗死患者急诊介入治疗后心力衰竭的疗效 [J]. 实用医学杂志, 2022, 38(11): 1410-1414. doi:10.3969/j.issn.1006⁃5725.2022.11.020
doi: 10.3969/j.issn.1006?5725.2022.11.020 |
54 |
PAOLISSO P, BERGAMASCHI L, GRAGNANO F, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry [J]. Pharmacol Res, 2023, 187: 106597. doi:10.1016/j.phrs.2022.106597
doi: 10.1016/j.phrs.2022.106597 |
55 |
VON LEWINSKI D, KOLESNIK E, TRIPOLT N J, et al. Empagliflozin in acute myocardial infarction: the EMMY trial [J]. Eur Heart J, 2022, 43(41): 4421-4432. doi:10.1093/eurheartj/ehac494
doi: 10.1093/eurheartj/ehac494 |
56 |
TENTOLOURIS A, VLACHAKIS P, TZERAVINI E, et al. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects [J]. Int J Environ Res Public Health, 2019, 16(16): 2965. doi:10.3390/ijerph16162965
doi: 10.3390/ijerph16162965 |
[1] | 龙珊,刘兴德,李甜甜,邹杨,周海燕. 冠心病患者经皮冠状动脉介入治疗术后合并焦虑抑郁机制及治疗的研究进展[J]. 实用医学杂志, 2023, 39(21): 2850-2856. |
[2] | 杜坤,陈文韬,鞠晓玲,汪洁. 皮肤胆固醇测定联合心电图平板运动对不典型胸痛患者冠心病诊断分析[J]. 实用医学杂志, 2023, 39(20): 2671-2675. |
[3] | 方定丰 陈海波 许嘉彬 马威 于冬冬 张萌 李浩亮 陈振宇. 血管内超声指导下经皮冠状动脉介入治疗的研究进展[J]. 实用医学杂志, 2022, 38(23): 3023-3026. |
[4] | 李英肖 宋学莲 吕彩霞 谢悦陶 张飞飞 党懿. 药物涂层球囊与药物洗脱支架治疗异质性支架内再狭窄的临床疗效分析 [J]. 实用医学杂志, 2021, 37(5): 637-642. |
[5] | 江小杰 刘丽赟 樊瀛丽. 经皮冠状动脉介入术后1年应用低剂量替格瑞洛的可行性及安全性研究 [J]. 实用医学杂志, 2021, 37(22): 2903-2907. |
[6] | 庞智英 杨飞 苏亚英 刘峰 汤林梦 崔书君. 冠状动脉CT血管成像联合基于CT的血流储备分数预测阻塞性冠心病主要不良心脏事件的价值 [J]. 实用医学杂志, 2021, 37(20): 2675-2680. |
[7] | 马春朋刘晓丽蔡丽丽朱爱红董雪飞马春明马利祥王庆胜聂绍平 .
HEART 风险评分在有冠心病的急性胸痛人群中的应用研究
[J]. 实用医学杂志, 2021, 37(2): 215-219. |
[8] | 崔留义, 毛幼林, 王瑞敏 . 依洛尤单抗对合并高脂血症的冠心病多支病变不完全血运重建患者的临床价值 [J]. 实用医学杂志, 2021, 37(11): 1466-1469. |
[9] | 宋风华, 郑颖颖, 唐俊楠, 郭倩倩, 张建朝, 程梦蝶, 蒋丽珠, 王凯, 刘志煜, 柏岩, 张金盈, .
平均血小板体积/淋巴细胞比值与冠心病经皮冠状动脉介入治疗术后长期死亡率的关系:一项队列研究
[J]. 实用医学杂志, 2020, 36(24): 3353-3357. |
[10] | 张紫萍, 方广, 郭秀彩. 从《冠心病合理用药指南》看尼可地尔在冠心病治疗中的作用[J]. 实用医学杂志, 2020, 36(22): 3033-3037. |
[11] | 黄静和, 陈思敏, 许研, 冷丽丽, 陈柏蓉. 空间QRS⁃T夹角与冠状动脉病变的关系及主要不良心脏事件的预测价值[J]. 实用医学杂志, 2020, 36(22): 3130-3134. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||